General anesthesia
Conditions
Interventions
Plain area I group:Sufentanil 0.3 µg/kg iv
Plain area II group:Remifentanil 0.3µg/kg·min iv
Plateau area I group:Sufentanil 0.3 µg/kg iv
Plateau area II group:Remifentanil 0.3µg/kg·min iv
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 65 years; 2.ASA classification is I or II; 3.Planning to perform general anesthesia surgery; 4.BMI is 19-29 kg/m^2; 5.Agree to voluntarily enroll patients in this trial; 6.Former residence plain area or plateau area (above 3000 meters above sea level).
Exclusion criteria
Exclusion criteria: 1.A history of allergy to general anesthetic drugs, a history of allergy to opioids, and a history of allergies to non-steroidal drugs; 2.History of neurological diseases; history of chronic pain; drug addiction and alcoholism; history of long-term use of opioids or nonsteroidal drugs; use of opioids or nonsteroidal drugs 48 hours before surgery; 3.Coronary heart disease, bronchial asthma, severe hypertension, severe blood system dysfunction, liver and kidney function, and electrolyte abnormalities; 4.History of gastrointestinal diseases (peptic ulcer, Crohn's disease, ulcerative colitis); 5.Respiratory insufficiency and respiratory failure; 6.Poor compliance and unable to complete the test according to the research plan; 7.Patients have participated in clinical trials of other drugs in the last 4 weeks; 8.For any reason, the researchers believe that there are any situations that are not suitable for selection.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Hemodynamics;Extubation time;Pain score;Vasoactive drugs;Inflammatory factors;Resuscitation residence time;Sedation and restlessness score;Analgesic remedy;Postoperative cognitive impairment;Tropisetron;Total amount of propofol;Anesthesia time;Bispectral index;Basic signs of the patient;Patient Controlled Analgesia Formula;Postoperative delirium;Postoperative Cardio-Cerebrovascular Accident;Opioid receptor genotype testing;Drug Metabolism Enzyme Test; | — |
Primary
| Measure | Time frame |
|---|---|
| hyperalgesia;Dosage of self-controlled analgesics;Adverse events; | — |
Countries
China
Contacts
Public ContactLi Yize
Tianjin Medical University General Hospital
Outcome results
None listed